SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : genelabs(gnlb)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jon Khymn who wrote (170)2/3/2000 9:29:00 AM
From: Toni Wheeler  Read Replies (1) of 233
 
***NEWS....

quotes.freerealtime.com

Web, looks like you made a timely investment in GNLB!!

News February 3, 08:01 Eastern Time

Genelabs Receives $5 Million for DARPA Research in 2000 Drug Discovery Grant Renewed for Third Year

<<<REDWOOD CITY, Calif., Feb 3, 2000 /PRNewswire via COMTEX/ -- Genelabs
Technologies, Inc. (Nasdaq: GNLB) announced today that the Defense Advanced
Research Projects Agency (DARPA) will fund $5 million to Genelabs for the
concluding third year of its research grant, slightly more than the $4.8 million
received by Genelabs from DARPA in 1999.

"The company made significant progress during 1999, identifying a number of
compounds that display antibacterial and antiviral activity," stated principal
investigator Thomas W. Bruice, MD, PhD, Genelabs Senior Director, Biochemistry
and Biophysics. "During the past year we have established an internal chemistry
group and are actively synthesizing and screening compounds for DNA-sequence
selectivity, double-stranded RNA structural selectivity and antimicrobial
activity. During this current grant year we will aggressively seek to expand on
the active chemical classes and to optimize the potency and selectivity of these
compounds."...>>>

My best,
T.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext